Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 25, 2024LeukemiaOpen Access

How risky is a second allogeneic stem cell transplantation?

View Full Paper
Ask AI
Bookmark
Share

Authors

OPOlaf PenackHumboldt-Universität zu BerlinMAMouad AbouqatebInsermCPChristophe PeczynskiInserm

Discussion

Loading...

Member takes

Implication

Analysis demonstrates improved two-year survival after second allogeneic stem cell transplantation in relapsed hematologic malignancies, suggesting feasibility of wider clinical use.

Key Points

  • Survival outcomes improve significantly following a second allogeneic stem cell transplantation for recurrent disease, surpassing historical therapeutic expectations.
  • Overall survival reaches 38% at two years, while non-relapse mortality is limited to 22% among recipients treated after hematologic malignancy recurrence.
  • Multivariate analysis of 3356 transplant procedures performed from 2011 to 2021 identifies prior acute gvhd and advanced recipient age as primary risk determinants.
  • Supports wider clinical adoption of second transplantation procedures, while emphasizing personalized recipient risk evaluation to mitigate non-relapse mortality.

Cite This Study

Penack et al. (2024) studied this question.

synapsesocial.com/papers/68e634d8b6db6435875c6c0dhttps://doi.org/10.1038/s41375-024-02318-3
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Proportional Hazards Model for the Subdistribution of a Competing Risk1999 · 13,956 citations
  2. 2Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study2024 · 45 citations
  3. 3Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study.2022 · 36 citations
  4. 4Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico2015 · 65 citations
  5. 5Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia—a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)2023 · 10 citations